Research-Use Dosing Conventions (Not Clinical Guidance) The figures below are reported from published studies and, for tirzepatide, its approved label
With the update, the FDA is urging patients taking Ozempic to talk to their doctors about the risks before being sedated
The market has seen strong traction from newer therapies such as: Eli Lillys Mounjaro (tirzepatide), launched in the UK in February 2024 and made available via the NHS in March 2025 Novo Nordisks Wegovy (semaglutide), introduced in the UK in September 2023 through specialist NHS weight-management services While these newer molecules dominate headlines, liraglutide remains a widely prescribed and proven therapy, and Biocons entry offers a more affordable alternativea key differentiator in public healthcare systems
This differentiation can be achieved through variations in dosage form, strength, or combinations, provided there is a documented medical need for such modifications. This pathway allows compounding pharmacies to serve patients with specific requirements not met by the standard FDA-approved medications
Ezure T, Amano S